…
Hims & Hers is expanding access to Eli Lillys branded weight loss drug Zepbound and diabetes drug Mounjaro as well…
WEDNESDAY, April 2, 2025 (HealthDay News) -- The telehealth company Hims & Hers Health is expanding its weight-loss offerings by…
Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldnt top the benchmark…
Hims & Hers Health shares rose 5% Tuesday after announcing it will offer Eli Lilly’s Zepbound and Mounjaro through its…
Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update…
The digital healthcare platform announced Tuesday that it has added Zepbound and generic liraglutide to its platform…
(HealthDay News) — The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to…
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…
Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldnt top the benchmark…
Telehealth platform Hims Hers Health, Inc. ($HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales…
Hims & Hers investors are clearly antsy about where the company’s weight-loss business is going and Tuesday’s announcement was supposed…
WEDNESDAY, April 2, 2025 (HealthDay News) -- The telehealth company Hims & Hers Health is expanding its weight-loss offerings by…
By I. Edwards HealthDay Reporter WEDNESDAY, April 2, 2025 (HealthDay News) -- The telehealth company Hims & Hers Health is…
We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on Substack by Antonio Linares. In this article, we…
We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on Substack by Antonio Linares. In this…
Charlotte (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse der Bank of America (BofA):
Die BofA bestätigt ihre "underperform"-Einschätzung für die Aktie von…
Hims & Hers adds Eli Lillys Zepbound to its platform at $1,899 monthly, boosting its weight loss portfolio…
The company said it will expand its weight-loss offerings with branded versions of Lillys tirzepatide.…
Daniel Grosslight, an analyst from Citi, maintained the Sell rating on Hims & Hers Health (HIMS – Research Report). The…
Eli Lilly said Tuesday it doesnt have any affiliation with Hims & Hers Health , adding that its weight-loss…
Die FDA hat dem Unternehmen vor kurzem die befristete Erlaubnis zur Herstellung ähnlicher GLP-1-Medikamente entzogen, was einen großen Teil der…
Truist maintains Hims & Hers stock hold rating, $39 target…
Der DAX hat gestern kräftig zugelegt und den Handelstag bei 22.539 Punkten beendet. Die Vorgaben aus Übersee sind größtenteils positiv.…
In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims hers…
Eli Lilly and Co:
* ELI LILLY:…
Hims & Hers health chief legal officer sells $89,863 in stock…
Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day,…
Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up…
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer…
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it…
Hims & Hers is adding Zepbound, Mounjaro, and the generic injection liraglutide to its platform.…
BofA maintains Hims & Hers stock underperform, $22 target…
Hims & Hers Health Inc. (HIMS) shares jumped over 8% to $31.98, hitting a high of $33.70, after announcing expanded…
Patients can now get a monthly Zepbound prescription through Hims’ telehealth platform.…
Hims & Hers is unable to sell copies of GLP-1 agonists after the FDA declared the shortage of those drugs…
BofA keeps an Underperform rating on Hims Hers with a $22 price target after the company indicated it is…
(Reuters) - Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys diabetes and weight-loss…
Telehealth firm Hims & Hers Health NYSE:HIMS said on Tuesday it plans to sell Eli Lillys NYSE:LLY weight-loss drug, as…
Telehealth firm Hims & Hers Health NYSE:HIMS said on Monday it plans to sell Eli Lillys NYSE:LLY diabetes and weight-loss…
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lillys (LLY) weight loss therapy tirzepatide & generic…
In a statement posted to the newsroom of Hims Hers (HIMS), Craig Primack stated in part: “In my experience…
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys weight-loss drug Zepbound on its…
Hims & Hers to sell Lilly’s Zepbound on its telehealth platform…
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lillys weight-loss drug, as it widens…
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys weight-loss drug Zepbound on its…
(Reuters) -Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lillys weight-loss drug Zepbound on…
Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to…
Price: 31.82, Change: +2.27, Percent Change: +7.68
...…
It is hard to get excited after looking at Hims & Hers Healths (NYSE:HIMS) recent performance, when its stock has...…